Influence of Surgical Resection and Post-Operative Complications on Survival following Adjuvant Treatment for Pancreatic Cancer in the ESPAC-1 Randomized Controlled Trial
- 1 January 2005
- journal article
- research article
- Published by S. Karger AG in Digestive Surgery
- Vol. 22 (5) , 353-363
- https://doi.org/10.1159/000089771
Abstract
Background/Aims: The influence of type of surgery and occurrence of post-operative complications on survival following adjuvant therapy for pancreatic cancer are uncertain. Methods: Cox proportional hazard modelling was used to investigate the influence of type of surgery and the presence of complications on survival in conjunction with clinico-pathological variables in the 550 patients of the ESPAC-1 adjuvant randomized controlled trial. Results: Standard Kausch-Whipple (KW) was performed in 282 (54%) patients, 186 (35%) had a pylorus-preserving (PP) KW, 39 (7%) had a distal pancreatectomy and 21 (4%) had a total pancreatectomy. Post-operative complications were reported in 140 (27%) patients. PP-KW patients survived longer with a median (95% CI) survival of 19.9 (17.3, 23.1) months compared to 14.8 (13.0, 16.7) for KW patients (χ2LR = 15.1, p < 0.001). KW patients were more likely however to have R1 margins (67 (24%) vs. 29 (16%), χ2 = 4.59, p = 0.032), poorly differentiated tumours (70 (26%) vs. 19 (10%), χ2 = 18.65, p < 0.001) and positive lymph nodes (165 (60%) vs. 81 (44%), χ2 = 11.32, p < 0.001). Post-operative complications did not significantly affect survival. Independent prognostic factors were tumour grade, nodal status and tumour size but not type of surgery or post-operative complications. There was a survival benefit for chemotherapy irrespective of the type of surgery or post-operative complications. Conclusions: The KW and PP-KW procedures did not significantly influence the hazard of death in the presence of tumour staging, demonstrating that ESPAC-1 surgeons showed good judgement in their choice of operation. Post-operative complications did not adversely affect the survival benefit from adjuvant chemotherapy.Keywords
This publication has 60 references indexed in Scilit:
- Neoadjuvant therapy for resectable pancreatic cancerSurgical Oncology Clinics of North America, 2004
- Chemotherapy for pancreatic cancerAlimentary Pharmacology & Therapeutics, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival DurationAnnals of Surgical Oncology, 2001
- Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomySurgery, 1997
- Lymph node metastases in carcinoma of the head of the pancreas regionBritish Journal of Surgery, 1995
- Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater—results of a controlled, prospective, randomised multicentre studyEuropean Journal Of Cancer, 1993
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- The Advantages of Pylorus-preserving Pancreatoduodenectomy in Malignant Disease of the Pancreas and Periampullary RegionAnnals of Surgery, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958